Other Events ·
NRX Pharmaceuticals received a final determination from the FDA on its Abbreviated New Drug Application for…
NRXPWNRX Pharmaceuticals, Inc.
NRX Pharmaceuticals received a final determination from the FDA on its Abbreviated New Drug Application for preservative-free ketamine, noting no major deficiencies in drug components but identifying a major deficiency regarding the twist-off cap of the luer lock vial due to potential deformation risks. Following an August 6, 2026 clarification meeting attended by senior FDA leadership, the agency committed to immediately reinitiating review and completing it in the shortest possible timeframe after receiving signed manufacturer certifications confirming production on existing approved lines. Management views the absence of drug-related deficiencies as a positive outcome, given that only 14% to 18% of ANDAs achieve first-round approval, and remains optimistic about resolving the packaging issue to enable commercial sales in 2026 amidst recognized ketamine shortages. NRX Pharmaceuticals operates in the pharmaceutical industry, developing and seeking regulatory approval for generic drug products.